Business
WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu
WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has kicked off construction of its new microbial manufacturing site for commercial production in the Wenjiang district of Chengdu, a renowned, vibrant hub for pharmaceutical development.
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"The microbial manufacturing site in Chengdu will be equipped with a 15,000L fermenter, enabling the production of 80 to 110 drug substance (DS) batches annually with expansion potential to 60,000L.","length":197,"tagName":"p"}]},{"val":[{"type":"text","content":"It will house China's first dual-chamber lyophilization production line and a vial filling line, with an overall drug product (DP) manufacturing capacity exceeding 10 million vials annually.","length":194,"tagName":"p"}]},{"val":[{"type":"text","content":"The new site will feature WuXi Biologics' recently launched microbial expression platform EffiXTM for the development and manufacturing of biologics with high yield, consistent quality, and superior stability and scalability.","length":229,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":620,"olType":false},{"type":"text","content":"CHENGDU, China, June 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has kicked off construction of its new microbial manufacturing site for commercial production in the Wenjiang district of Chengdu, a renowned, vibrant hub for pharmaceutical development.","length":369,"tagName":"p"},{"type":"text","content":"Spanning an area of 95,000 square meters, the new site is dedicated to a drug substance (DS) facility and a drug product (DP) facility for commercial manufacturing, encompassing a wide array of modalities, such as peptides,antibody fragments, plasmid DNA, enzymes, cytokines, and virus-like particles (VLPs). Scheduled to complete GMP release for production by the end of 2026, the site will be equipped with a 15,000L fermenter, enabling an annual production capacity of 80 to 110 DS batches. In the long run, capacity will be able to expand to 60,000L. Notably, the facility will house China's first dual-chamber lyophilization production line alongside a vial filling line, with overall DP manufacturing capacity exceeding 10 million vials annually, a significant enhancement of WuXi Biologics' commercial manufacturing capabilities for the global market.","length":876,"tagName":"p"},{"type":"text","content":"The state-of-the-art facilities will feature WuXi Biologics' recently launched microbial expression pl...